Targeting Prostate Cancer Metastasis
Abstract
WASF3 functions as a key regulator in controlling metastasis of prostate cancer and inhibiting it prevents metastasis. There are no drugs available to target WASF3 directly, but there are many FDA approved drugs target the other proteins that it interacts with. Using preclinical animal models of prostate cancer, we aim to investigate whether the proposed drugs that target WASF3-dependent pathways can be repurposed in an attempt to suppress prostate cancer metastasis. The major achievement of our research in the first year of this funding is: 1) have screened the effects of more than 40 drugs on invasion using cultured prostate cancer cells and found that targeting multiple points in WASF3 regulatory network by co-treatment was more efficient to suppress invasion than either drug alone; 2) we have established drug toxicity and the effective dose in zebrafish and found the best performing strategies using zebrafish-metastasis models. This has allowed us to transfer the findings to in vivo mouse metastasis assays. If success, it provides a great means to improve the quality of life for metastatic prostate cancer patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2015
- Accession Number
- ADA621823
Entities
People
- Yong Teng
Organizations
- Augusta University